Avecho Biotechnology Limited (AVEFF) Stock Price & Analysis
Avecho Biotechnology Limited (AVEFF) — price $0.0045 (0.00%), as of the Nov 19, 2026 trading session; market cap $17.4M.
Educational signal · not a buy or sell recommendation · How to read this
Avecho Biotechnology Limited · AVEFF
Avecho Biotechnology Limited specializes in innovative drug delivery systems through its patented Targeted Penetration Matrix (TPM) technology. The company serves diverse sectors, including pharmaceuticals and animal health, focusing on enhancing product efficacy and health outcomes.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0045 | |
| Change on the day | 0.00% | |
| 52-week range | $0.003 – $0.0045 | |
| Market capitalisation | $17.4M | |
| Shares traded on the day | 300.0K |
Price & events
Other perspectives
Council score for Avecho Biotechnology (AVEFF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Avecho Biotechnology (AVEFF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Avecho Biotechnology Limited (AVEFF) is the company analyzed here. It employs 15 people and is led by Paul Gavin. In Q2 FY2026 it reported revenue of A$59,518 and net income of -A$2M. The market values it at $17.4M.
What do the latest results show for Avecho Biotechnology (AVEFF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of A$59,518.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | A$59,518 | -A$2M | A$0.00 (diluted) |
| Q4 FY2025 | A$677,425 | -A$2M | A$0.00 (diluted) |
| Q2 FY2025 | A$560,069 | -A$3M | -A$0.0008 (diluted) |
| Q4 FY2024 | A$820,484 | -A$946,000 | -A$0.0002 (diluted) |
What are the financial strengths and risks for Avecho Biotechnology (AVEFF)?
Short answer · as of
The distress and quality screens read Altman Z -44.78 · Piotroski F 2. Trailing ratios: ROA -43.6% · current ratio 5.38 · earnings yield -8.2% · free-cash-flow yield -7.5%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -44.78 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held AVEFF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AVEFF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Avecho Biotechnology (AVEFF)?
Common Questions About AVEFF
These answers are editorial: 1 of these 1 answer is drawn from the AVEFF research dossier (written Jun 14, 2026 by gpt-4o-mini). Figures in this section are not part of the source register.
What are the main risks for AVEFF?
Avecho Biotechnology Limited faces several risks, including regulatory challenges that could hinder the approval process for its products. The company also has a negative profit margin, which may indicate financial instability and affect its operational capabilities.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 8 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com